Biren Amin
Stock Analyst at Piper Sandler
(3.38)
# 924
Out of 5,149 analysts
69
Total ratings
45.9%
Success rate
5.97%
Average return
Main Sectors:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $125 → $140 | $86.35 | +62.13% | 1 | Feb 26, 2026 | |
| OKYO OKYO Pharma | Initiates: Overweight | $7 | $1.70 | +311.76% | 1 | Feb 20, 2026 | |
| CATX Perspective Therapeutics | Initiates: Overweight | $16 | $5.17 | +209.48% | 1 | Feb 19, 2026 | |
| IRD Opus Genetics | Initiates: Overweight | $7 | $4.25 | +64.71% | 1 | Nov 25, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | $48 | $21.59 | +122.36% | 1 | Nov 5, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $15 → $16 | $15.87 | +0.82% | 12 | Oct 30, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $93 → $98 | $64.53 | +51.87% | 4 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $51 → $67 | $13.15 | +409.51% | 2 | Oct 10, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Overweight | $21 → $31 | $10.76 | +188.10% | 2 | Oct 3, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Overweight | $76 → $95 | $51.88 | +83.11% | 2 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $6 | $3.04 | +97.37% | 1 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4.5 → $4 | $2.38 | +68.07% | 1 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $17 | $5.96 | +185.23% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $2.53 | +176.68% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $26.20 | +45.04% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $5.53 | +117.00% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $31.93 | +122.36% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $8.21 | +326.31% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $21.54 | -2.51% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $114.05 | +0.83% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $20.16 | +58.73% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $3.18 | -5.66% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $2.38 | +2,841.18% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.19 | +27,467.57% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $5.11 | +369.67% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $4.53 | +650.55% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $0.35 | +142,472.00% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $9.84 | +42.28% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $766.66 | -9.87% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $4.81 | +107.90% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $52.83 | +91.18% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $131.14 | -47.38% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $474.27 | -67.32% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $6.86 | +1,882.51% | 4 | Mar 6, 2017 |
Kymera Therapeutics
Feb 26, 2026
Maintains: Overweight
Price Target: $125 → $140
Current: $86.35
Upside: +62.13%
OKYO Pharma
Feb 20, 2026
Initiates: Overweight
Price Target: $7
Current: $1.70
Upside: +311.76%
Perspective Therapeutics
Feb 19, 2026
Initiates: Overweight
Price Target: $16
Current: $5.17
Upside: +209.48%
Opus Genetics
Nov 25, 2025
Initiates: Overweight
Price Target: $7
Current: $4.25
Upside: +64.71%
Ascentage Pharma Group International
Nov 5, 2025
Initiates: Overweight
Price Target: $48
Current: $21.59
Upside: +122.36%
Sarepta Therapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $15.87
Upside: +0.82%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $93 → $98
Current: $64.53
Upside: +51.87%
LENZ Therapeutics
Oct 10, 2025
Maintains: Overweight
Price Target: $51 → $67
Current: $13.15
Upside: +409.51%
Ocular Therapeutix
Oct 3, 2025
Maintains: Overweight
Price Target: $21 → $31
Current: $10.76
Upside: +188.10%
Monopar Therapeutics
Sep 25, 2025
Maintains: Overweight
Price Target: $76 → $95
Current: $51.88
Upside: +83.11%
Jul 10, 2025
Assumes: Overweight
Price Target: $6
Current: $3.04
Upside: +97.37%
Jun 26, 2025
Reiterates: Overweight
Price Target: $4.5 → $4
Current: $2.38
Upside: +68.07%
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $5.96
Upside: +185.23%
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $2.53
Upside: +176.68%
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $26.20
Upside: +45.04%
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $5.53
Upside: +117.00%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $31.93
Upside: +122.36%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $8.21
Upside: +326.31%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $21.54
Upside: -2.51%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $114.05
Upside: +0.83%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $20.16
Upside: +58.73%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $3.18
Upside: -5.66%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $2.38
Upside: +2,841.18%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.19
Upside: +27,467.57%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $5.11
Upside: +369.67%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $4.53
Upside: +650.55%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $0.35
Upside: +142,472.00%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $9.84
Upside: +42.28%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $766.66
Upside: -9.87%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $4.81
Upside: +107.90%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $52.83
Upside: +91.18%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $131.14
Upside: -47.38%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $474.27
Upside: -67.32%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $6.86
Upside: +1,882.51%